Navidea Biopharmaceuticals Inc. announced Thursday that its investigational beta-amyloid imaging agent, NAV4694, produced highly differentiated images in the first cohort of subjects enrolled in the Company’s Phase 2b positron emission tomography or PET imaging study of subjects with Mild Cognitive Impairment or MCI. {read more here}